BRIEF-AstraZeneca gains FDA backing for Bydureon BCise

Oct 23 (Reuters) - AstraZeneca Plc

* US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes

* Bydureon BCise will be available for patients in US in Q1 of 2018

* a regulatory application for new autoinjector device has also been accepted by european medicines agency Source text for Eikon: Further company coverage: (London newsroom)